The ‘Saskatchewan’ compounds appear to be highly potent chemopotentiators – drugs that enhance the activities of existing chemotherapeutic treatments. The compounds have also demonstrated activity in neurological and other degenerative diseases. However, it is YM Biosciences’ intention to focus its own resources on the oncology applications and seek partners in order to advance the neurological applications.
“This new technology platform represents an additional opportunity for YM BioSciences to expand its already significant franchise in cancer through the development of a new generation of combination drug treatments that enhance the cytotoxic activities of chemotherapeutic drugs,” said David Allan, chairman and CEO.
The company’s current lead drug, tesmilifene, is currently undergoing a phase III trial to test its ability to enhance the therapeutic effect of chemotherapy in metastatic breast cancer.